Literature DB >> 24729682

Characteristics of intraretinal deposits in acute central serous chorioretinopathy.

Andrea M Plateroti1, Matthew T Witmer1, Szilárd Kiss1, Donald J D'Amico1.   

Abstract

PURPOSE: To describe the temporal and spatial characteristics of intraretinal deposits in patients with acute central serous chorioretinopathy (CSC) using spectral domain optical coherence tomography (OCT).
MATERIALS AND METHODS: We retrospectively reviewed the medical records of all patients that presented with acute CSC to Weill Cornell Medical College from January 2012 to May 2013. Acute CSC was defined as a diagnosis of CSC within 4 months of the onset of symptoms. Only one eye per patient was included in the study. Each patient was imaged with spectral domain OCT at the initial office visit. The decision to reimage these patients was made by the treating physician.
RESULTS: A total of 25 patients (25 eyes; 17 men and eight nonpregnant women) were included in this review. Seven of 25 patients (28%) demonstrated intraretinal deposits within the outer plexiform layer during the initial OCT, with deposits appearing as early as the same day as the onset of symptoms. A total of 25 of 25 patients (100%) demonstrated intraretinal deposits in the outer nuclear layer upon initial (76%) or follow-up OCT, as early as 2 days after the onset of symptoms. A total of 24 of 25 patients (96%) demonstrated deposits in the external limiting membrane upon a follow-up OCT, as early as 7 days from symptoms appearing. A total of 24 of 25 patients (96%) developed intraretinal deposits in the inner segment/outer segment layer upon follow-up OCT, appearing as early as 14 days after symptom onset. At the time of resolution of subretinal fluid, 20 of 25 patients (80%) demonstrated intraretinal deposits.
CONCLUSION: Intraretinal deposits are present in the outer retinal layers in patients with acute CSC, with the deposits appearing progressively deeper within the retina as the condition evolves. Upon resolution of subretinal fluid, the deposits slowly resolve.

Entities:  

Keywords:  acute central serous chorioretinopathy; intraretinal deposits; spectral domain OCT

Year:  2014        PMID: 24729682      PMCID: PMC3979800          DOI: 10.2147/OPTH.S48894

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

Central serous chorioretinopathy (CSC) is a disorder characterized by serous retinal detachment and/or retinal pigmented epithelial (RPE) detachments associated with a thickened choroid. These changes are most often confined to the macula and associated with leakage of fluid through the RPE into the subretinal space.1 CSC is a common clinical diagnosis, especially in young to middle-aged adults,2 and has been associated with the use of several medications (chronic corticosteroid therapy) and several systemic conditions (hypertensive diseases). Patients usually present with blurred vision, metamorphopsia, micropsia3 or a relative central scotoma.4 Optical coherence tomography (OCT) has the ability to evaluate intraretinal changes and abnormalities,1,5 with a resolution of several microns. OCT imaging can noninvasively identify the presence and extent of subretinal fluid (SRF) and pigmented epithelium detachments, and it is also useful for assessing the resolution of SRF and morphological changes during normal disease progression. With the new generation of spectral domain OCT (SD-OCT), topographic changes in CSC can be visualized with two- and three-dimensional reconstructions; it also offers the ability to accurately evaluate volumetric measurements.6 Many authors have reported the presence of amorphous material in patients with CSC, which is usually located anterior to the RPE.7–11 These deposits, however, are also located within the retina during the course of this condition. The aim of this study was to describe the location and duration of these intraretinal deposits in patients with acute CSC using SD-OCT and the correlation of these deposits with the trend of the disease.

Materials and methods

We retrospectively reviewed the medical records of 25 patients (25 eyes) (17 men and 8 nonpregnant women) who presented to Weill Cornell Medical College from January 2012 to May 2013 and were diagnosed with acute CSC. Acute CSC was defined as the presence of a serous detachment of the macular neurosensory retina upon OCT, focal leakage of fluorescein on fluorescein angiography and the onset of such symptoms as metamorphopsia (94%), decreased visual acuity (VA) (90%), decreased color vision (43%), and micropsia (37%) within the previous 4 months. Eyes with other macular abnormalities were excluded. Measurements of the best-corrected visual acuity (BCVA), dilated fundus examination, and SD-OCT with a Heidelberg Spectralis® (Heidelberg Engineering, Heidelberg, Germany) were performed at every visit. Fluorescein angiography was performed at the baseline visit. The treating physician determined the follow-up schedule of all patients. The OCT scans of each subject were evaluated at the initial visit and at each follow-up visit for the presence and characteristics of intraretinal deposits.

Results

The mean age of men included in the study was 41 (range 26–69) years, and their BCVA was 0.65, with a standard deviation (SD) 0.33. The mean age of women included in the study was 54 (range 40–72) years, and their mean BCVA was 0.73 (SD 0.17). Seven of 25 patients (28%) presented with intraretinal deposits within the outer plexiform layer on their OCT during their initial visit. These deposits appeared as early as the same day as the onset of symptoms (average duration of symptoms was 4 days, SD 2.83, range 1–7). Nineteen of 25 (76%) patients demonstrated intraretinal deposits in the outer nuclear layer (ONL) upon their initial OCT. These deposits appeared as early as 2 days after the onset of symptoms (average duration of symptoms was 37.8 days, SD 34.97, range 2–120). At some point during follow-up, 100% of patients demonstrated intraretinal deposits on the OCT in the ONL. A total of 24 of 25 patients (96%) demonstrated deposits in the external limiting membrane at some point during their follow-up OCT. These deposits appeared as early as 7 days from the onset of symptoms (average duration of symptoms was 53.17 days, SD 46.18, range 7–120). A total of 24 of 25 patients (96%) developed intraretinal deposits in the inner-segment/outer-segment layers at some point during their follow-up. These deposits appeared as early as 14 days after the onset of symptoms (average duration of symptoms was 73.46 days, SD 58.98, range 14–120). At the time of resolution of SRF, 20 of 25 patients (80%) demonstrated intraretinal deposits. Thanks to multiple OCT scans, the location of the intraretinal deposits followed a progression to deeper layers of the retina during follow-up. Table 1 demonstrates 13 patients where it was possible to observe the evolution of the location of intraretinal deposits over time. The characteristics of intraretinal deposits are better clarified in Figure 1, which demonstrates how they followed a temporal and spatial trend towards their appearance in deeper layers of the retina as the disease progressed.
Table 1

Progression of intraretinal deposits in acute central serous chorioretinopathy patients

PatientLayer of intraretinal deposits
OPLONLELMIS/OS
12 days2 days109 days109 days
247 days47 days70 days
37 days7 days118 days118 days
41 day5 days28 days28 days
548 days48 days115 days
630 days30 days105 days
77 days7 days97 days
82 days64 days64 days64 days
97 days7 days14 days76 days
102 days7 days
117 days7 days7 days55 days
1215 days15 days70 days
1314 days14 days110 days

Abbreviations: OPL, outer plexiform layer; ONL, outer nuclear layer; ELM, external limiting membrane; IS/OS, inner-segment/outer-segment junction.

Figure 1

Number of days plotted against the four main involved layers. The number of days is represented on the vertical axis; the horizontal axis shows the four layers. The square dots in the chart indicate the average (blue dots) and the standard deviation (red dots) of days since the onset of symptoms in which deposits showed up in one of the involved layers. The figure can help better understanding of the time progression of deposit through the layers.

Abbreviations: OPL, outer plexiform layer; ONL, outer nuclear layer; ELM, external limiting membrane; IS/OS, inner segment/outer segment; SD, standard deviation.

The OCT images of Figures 2 and 3, taken from two different patients, demonstrate how these deposits appear in the deeper retinal layers as the duration of the disease increases. Figure 2A shows the OCT of a patient 2 days after the onset of symptoms. There are traces of intraretinal deposits in the outer plexiform layer. In the same OCT, deposits were also found in the ONL (Figure 2B). Figure 3A represents an OCT taken 10 days after symptom onset of a different patient, and shows intraretinal deposits in the external limiting membrane. Figure 3B was taken on the same patient as Figure 2A, 15 days after the beginning of symptoms. SRF was completely resolved, but the red arrows indicate how deposits were still present in the inner-segment/outer-segment layer.
Figure 2

(A and B) Optical coherence tomography of a patient (patient 1) with acute central serous chorioretinopathy, taken 2 days after the onset of symptoms. The red circles indicate intraretinal deposits (small white dots) inside the outer plexiform layer (A) and the outer nuclear layer (B).

Figure 3

Optical coherence tomography of a patient (patient 12) with acute central serous chorioretinopathy, taken 10 (A) and 15 days (B) after the onset of symptoms. The red circle and red arrows indicate intraretinal deposits (small white dots), respectively, inside the external limiting membrane (A) and the inner-segment/outer-segment junction (B). (B) The subretinal fluid is completely resolved, but some deposits are still present even after this resolution.

Discussion

The role of OCT as a noninvasive way of imaging the retina is well known.12–17 Several papers have described OCT findings in eyes with CSC and have documented the presence of subretinal or supra-RPE deposits, but very few reports discuss intraretinal deposits.1,11,18,19 This study demonstrates the evolution of intraretinal deposits as they appear more deeply within the outer retina as the disease progresses. The intraretinal deposition described in this study appears to be a primary manifestation of CSC, but it differs in character and location from that seen in choroidal neovascularization (CNV). In fact, in acute stages of CNV, the two most common materials deposited under the retina are blood and lipid. Blood is most commonly seen near the area of CNV, while lipid is more common at the rim of the detachment at the outer-segment layer.8 The distribution of material in this study appears to be limited to the area of current or prior serous detachment. The composition of the intraretinal deposits is not well established. Histopathological studies20,21 have shown the presence of fibrin inside the deposits and of a high protein content within the SRF. The material does not appear to be lipid; the patients in this and previous studies8 did not appear to have systemic inflammatory disease or evidence of ocular inflammation. The pathogenesis of CSC has been hypothesized to be the dysfunction of the RPE cells, perhaps in the ion-pumping mechanism.22,23 Similarly, we hypothesize that the intraretinal deposits may accumulate secondary to the inability of the RPE cells to pump the highly proteinaceous SRF from the intraretinal and subretinal spaces. In conclusion, we have shown a chronological trend to the appearance of intraretinal deposits in acute CSC that is dependent on the duration and onset of symptoms. The understanding of this process may be of clinical value in allowing physicians to better understand the staging of CSC and helping them in terms of diagnosing, monitoring, and deciding when to treat patients with this condition.
  22 in total

1.  Evaluation of central serous chorioretinopathy with optical coherence tomography.

Authors:  T Iida; N Hagimura; T Sato; S Kishi
Journal:  Am J Ophthalmol       Date:  2000-01       Impact factor: 5.258

2.  [Three-dimensional imaging in central serous chorioretinopathy].

Authors:  G Stock; C Ahlers; R Sayegh; M Ritter; S Kolar; I Golbaz; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

Review 3.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

4.  Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT).

Authors:  Winfried Goebel; Tatjana Kretzchmar-Gross
Journal:  Retina       Date:  2002-12       Impact factor: 4.256

5.  Alterations of retinal pigment epithelium in central serous chorioretinopathy.

Authors:  Yasuhiko Hirami; Akitaka Tsujikawa; Manabu Sasahara; Norimoto Gotoh; Hiroshi Tamura; Atsushi Otani; Michiko Mandai; Nagahisa Yoshimura
Journal:  Clin Exp Ophthalmol       Date:  2007-04       Impact factor: 4.207

6.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

7.  Experimental serous retinal detachment and focal pigment epithelial damage.

Authors:  A Negi; M F Marmor
Journal:  Arch Ophthalmol       Date:  1984-03

8.  Cystoid macular degeneration in chronic central serous chorioretinopathy.

Authors:  Tomohiro Iida; Lawrence A Yannuzzi; Richard F Spaide; Natalie Borodoker; Cynthia A Carvalho; Silvana Negrao
Journal:  Retina       Date:  2003-02       Impact factor: 4.256

9.  Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography.

Authors:  Hyung Chan Kim; Won Bin Cho; Hyewon Chung
Journal:  Korean J Ophthalmol       Date:  2012-09-24

10.  Correlation of spectral domain optical coherence tomography findings in acute central serous chorioretinopathy with visual acuity.

Authors:  Unnikrishnan Nair; Sunil Ganekal; Manoj Soman; Kgr Nair
Journal:  Clin Ophthalmol       Date:  2012-11-26
View more
  6 in total

1.  Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Hasan Gunes; Gokhan Demir
Journal:  Lasers Med Sci       Date:  2021-01-07       Impact factor: 3.161

2.  Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy.

Authors:  Wei-Yu Lai; Cheui-Lien Tseng; Tsung-Tien Wu; Huey-Shyan Lin; Shwu-Jiuan Sheu
Journal:  BMJ Open Ophthalmol       Date:  2017-08-16

3.  Evaluation of choroidal hyperreflective dots in acute and chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Alexandre Matet; Mohammed Abdul Rasheed; Abhilash Goud; Kiran Kumar Vuppurabina; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2019-11       Impact factor: 1.848

4.  Baseline Predictive Factors of Visual Outcome and Persistence of Subretinal Fluid Based on Morphologic Changes in Spectral Domain Optical Coherence Tomography in Patients with Idiopathic Central Serous Chorioretinopathy.

Authors:  Barsha Suwal; Deepak Khadka; Arjun Shrestha; Sangeeta Shrestha; Nirsara Shrestha; Bijay Khatri
Journal:  Clin Ophthalmol       Date:  2019-12-09

Review 5.  Central serous chorioretinopathy: Current update on pathophysiology and multimodal imaging.

Authors:  George Joseph Manayath; Ratnesh Ranjan; Vanee Sheth Shah; Smita S Karandikar; Veerappan R Saravanan; Venkatapathy Narendran
Journal:  Oman J Ophthalmol       Date:  2018 May-Aug

Review 6.  Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.

Authors:  Mary Ho; Gabriel Li; Andrew Mak; Danny Ng; Lawrence Iu; Frank Lai
Journal:  J Ophthalmol       Date:  2021-07-24       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.